The Chinese Solar Machine Layer by Layer Fire in the Library The Mystery Behind Anesthesia
Severe, even life-threatening peanut allergies afflict 3 million people in the United States alone. The only protection now available is to avoid peanuts and their derivatives. While it's easy to eschew peanut butter sandwiches, who's to know if the chips at the office party were fried in peanut oil? Houston-based Tanox has begun human testing of a once-a-month injection to protect the peanut-averse from accidental exposure. The drug, Hu-901, is an antibody that blocks the immune reaction responsible for swelling and itching. People taking it probably won't be able to eat nuts daily, but they should have more time to get help if they do eat those chips.
If Hu-901 is effective in preventing peanut allergies, Tanox may investigate its use against other food allergies. The company hopes a similar antibody to treat seasonal allergies and asthma will get regulatory approval by mid-2001.
To read the entire article you must log in:
Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.
Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.
Our list of the 50 most innovative companies, including the following: